REG - Oxford BioDynamics - Issue of shares, Director / PDMR holdings and TVR

Oxford BiodynamicsAnnouncement

24/12/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241224:nRSX2011Ra&default-theme=true

RNS Number : 2011R  Oxford BioDynamics PLC  24 December 2024

Oxford BioDynamics
("OBD" or the "Company" and, together with its subsidiaries, the "Group")

Issue of shares in lieu of salary,

Director / PDMR shareholdings &

Total voting rights

Oxford, UK - 24 December 2024 - Oxford BioDynamics, Plc (AIM: OBD, the
Company), a precision clinical diagnostics company bringing specific and
sensitive tests to the practice of medicine based on OBD's EpiSwitch® 3D
genomics platform, announces the issue of 2,742,657 ordinary shares of 1 pence
each ("Ordinary Shares") at a price of 1.1 per share (the "New Ordinary
Shares") to its directors, PDMRs and certain other senior staff members to
satisfy part of their salaries and fees, in line with the Company's ongoing
strategy to preserve its cash resources as announced on 14 October 2024. The
issue price is equal to the closing market price of the Company's Ordinary
Shares on 23 December 2024, being the last practicable date prior to the issue
of the New Ordinary Shares.

The New Ordinary Shares being issued have been allocated to the following
directors and PDMRs:

 

 Director / PDMR           Position                  Number of New Ordinary Shares issued  Resultant shareholding in the Company  % of the issued share capital of the Company
 Dr Alexandre Akoulitchev  Chief Scientific Officer  229,584                               7,562,296                              2.37%
 Paul Stockdale            Chief Financial Officer   212,547                               1,077,919                              0.34%
 Matthew Wakefield         Non-Executive Chairman    115,949                               1,616,614                              0.51%
 Dr David Holbrook         Non-Executive Director    58,671                                159,964                                0.05%
 Thomas Guiel              Chief Operating Officer   261,343                               1,288,146                              0.40%
 Dr Ewan Hunter            Chief Data Officer        194,720                               722,754                                0.23%

 

Application has been made for the New Ordinary Shares to be admitted to
trading on AIM ("Admission") and it is expected that Admission will occur at
8.00 a.m. on or around 31 December 2024. The New Ordinary Shares have been
issued as fully paid and rank pari passu in all respects with the existing
Ordinary Shares.

Following Admission, the Company's issued share capital will consist of
319,319,226 Ordinary Shares. There are no shares held in treasury. Therefore,
the Company's total number of Ordinary Shares in issue and voting rights will
be 319,319,226 and this figure may be used by Shareholders from Admission as
the denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in, the
Company under the FCA's Disclosure Guidance and Transparency Rules.

Further details of the PDMR dealings are included below. This information has
been provided in accordance with Article 5(1)(b) of the Market Abuse
Regulation (EU) No 596/2014 which is part of UK law by virtue of the European
Union (Withdrawal) Act 2018.

-Ends-

 

For more information:

 Oxford BioDynamics Plc                      +44 (0)1865 518910

Matthew Wakefield, Non-Executive Chairman

Paul Stockdale, CFO
 Shore Capital                               +44 (0)20 7408 4090

(Nominated Adviser and Broker to OBD)

Stephane Auton

Lucy Bowden
 WG Partners                                 +44 (0)20 3705 9330

(Joint Broker to OBD)

David Wilson / Claes Spång /

Satheesh Nadarajah / Erland Sternby
   Oak Securities                            +44 (0)20 3973 3678

   (Joint Broker to OBD)

  Jerry Keen / Henry Clarke
 Vigo Consulting                             +44 (0)20 7390 0230
 (Media / Analyst enquiries for OBD)

Rozi Morris                                obd@vigoconsulting.com

 

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company,
advancing personalized healthcare by developing and commercializing precision
clinical diagnostic tests for life-changing diseases.

Currently OBD has two commercially available products: the EpiSwitch® PSE
(https://www.94percent.com/) (EpiSwitch Prostate Screening test) and
EpiSwitch® CiRT (https://mycirt.com/index.html) (Checkpoint Inhibitor
Response Test) blood tests. PSE boosts the predictive accuracy of a PSA test
from 55% to 94% when testing the presence or absence of prostate cancer. CiRT
is a highly accurate (85%) predictive response test to immuno-oncology
checkpoint inhibitor treatments.

The tests are based on OBD's proprietary 3D genomic biomarker platform,
EpiSwitch® which enables screening, evaluation, validation and monitoring of
biomarkers to diagnose patients or determine how individuals might respond to
a disease or treatment.

OBD's clinical smart tests have the potential to be used across a broader
range of indications, and new tests are being developed in the areas of
oncology, neurology, inflammation, hepatology and animal health.

The Group's headquarters and UK laboratories are in Oxford, UK. Its US
operations and clinical laboratory are in Maryland, USA, along with a
reference laboratory in Penang, Malaysia.

OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more
information, please visit the Company's website, www.oxfordbiodynamics.com
(https://www.oxfordbiodynamics.com/) ,  X (@OxBioDynamics) or LinkedIn
(https://www.linkedin.com/company/oxford-biodynamics/) .

 

The notifications below, made in accordance with the requirements of the UK
Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them.

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         1)    Dr Alexandre Akoulitchev

                                                                   2)    Paul Stockdale

                                                                   3)    Matthew Wakefield

                                                                   4)    Dr David Holbrook

                                                                   5)    Thomas Guiel

                                                                   6)    Dr Ewan Hunter
 2    Reason for the notification

 a)   Position/status                                              1)    Chief Scientific Officer, Director

                                                                   2)    Chief Financial Officer, Director

                                                                   3)    Non-Executive Director

                                                                   4)    Non-Executive Director

                                                                   5)    Chief Operating Officer, PDMR

                                                                   6)    Chief Data Officer, PDMR
 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Oxford Biodynamics plc

 b)   LEI                                                          2138005Y1TK258O5U928

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  Ordinary Shares

      Identification code

                                                                   ISIN: GB00BD5H8572
 b)   Nature of the transaction                                    Issue of New Ordinary Shares in lieu of salary

 c)   Price(s) and volume(s)                                       Price(s)  Volume(s)

                                                                 1)  1.1p      229,584
                                                                   2)  1.1p      212,547
                                                                   3)  1.1p      115,949
                                                                   4)  1.1p      58,671
                                                                   5)  1.1p      261,343
                                                                   6)  1.1p      194,720
 d)   Aggregated information

      - Aggregated volume                                          N/A - single transactions

      - Price

 e)   Date of the transaction                                      23 December 2024

 f)   Place of the transaction                                     London Stock Exchange (XLON)

d)

 

Aggregated information

- Aggregated volume

- Price

 

 

N/A - single transactions

e)

 

Date of the transaction

23 December 2024

f)

Place of the transaction

London Stock Exchange (XLON)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCDZMZZFFNGDZZ